NEW YORK, September 29, 2017 /PRNewswire/ --
If you want a Stock Review on TRXC, DXTR, MZOR, or XRAY then come overto http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session flat; the Dow Jones Industrial Average edged
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished Thursday's session 2.19% lower at $1.34. A total volume of 873,927 shares was traded. The Company's shares have advanced 50.02% in the past month and 94.20% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 46.33% and 32.72%, respectively. Furthermore, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have a Relative Strength Index (RSI) of 62.72. Free research report on TRXC is available at:
Shares in Redwood City, California-based Dextera Surgical Inc. ended at $0.28, up 0.77% from the last trading session. The stock recorded a trading volume of 2.03 million shares. The stock is trading below its 50-day moving average by 4.67%. Moreover, shares of Dextera Surgical, which designs and manufactures proprietary stapling devices for minimally invasive surgical procedures in the US, Japan, Germany, and internationally, have an RSI of 43.73. The complimentary research report on DXTR can be downloaded at:
Caesarea, Israel-based Mazor Robotics Ltd's stock ended yesterday's session 1.07% higher at $48.98 with a total trading volume of 231,487 shares. The Company's shares have advanced 16.70% in the past month, 43.68% over the previous three months, 101.07% in the last twelve months, and 123.45% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.06% and 49.59%, respectively. Additionally, shares of Mazor Robotics, which together with its subsidiary, Mazor Robotics Inc., is engaged in the development, production, marketing, and servicing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US, Western Europe, Eastern Europe, and Asia, have an RSI of 61.94. Visit us today and access our complete research report on MZOR at:
On Thursday, shares in York, Pennsylvania headquartered DENTSPLY SIRONA Inc. recorded a trading volume of 996,262 shares. The stock finished the day 0.90% lower at $59.23. The Company's shares have advanced 6.34% in the last one month. The stock is trading above its 50-day moving average by 1.60%. Furthermore, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have an RSI of 53.82. Get free access to your research report on XRAY at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All